Elsevier Inc.

SHERPA: Unknown

People

  1. Giralt
    Giralt
  2. Hultcrantz
    Hultcrantz
  3. Hassoun
    Hassoun
  4. Korde
    Korde
  5. Lesokhin
    Lesokhin
  6. Mailankody
    Mailankody
  7. Scordo
    Scordo
  8. Shah
    Shah
  9. Landau
    Landau
  10. Shah
    Shah

Groups

  1. Center for Hematologic Malignancies (114)
  2. Sloan Kettering Institute Postdocs (114)
  3. Department of Medicine (106)
  4. Hematologic Malignancies, Division of (104)
  5. Bone Marrow Transplant (65)
  6. GSK Faculty (62)
  7. Survivorship Research (49)
  8. Hematologic Malignancies Research (48)
  9. Sloan Kettering Institute Faculty (44)
  10. Executive Committee, Center for Hematologic Malignancies (40)
Search Within
  1. "Center for Hematologic Malignancies"
  2. "Meeting abstract"
  3. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (114)
Groups
  1. Center for Hematologic Malignancies (114)
  2. Sloan Kettering Institute Postdocs (114)
  3. Department of Medicine (106)
  4. Hematologic Malignancies, Division of (104)
  5. Bone Marrow Transplant (65)
  6. GSK Faculty (62)

More Groups

People
  1. Malin Hultcrantz (38)
  2. Sergio Giralt (38)
  3. Alexander Lesokhin (29)
  4. Gunjan Shah (29)
  5. Hani Hassoun (29)
  6. Michael Scordo (29)

More People

Years
  1. 2024 (2)
  2. 2023 (25)
  3. 2022 (17)
  4. 2021 (5)
  5. 2020 (7)
  6. 2019 (14)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (42)
  2. Biology of Blood and Marrow Transplantation (41)
  3. Journal of Thoracic Oncology (8)
  4. International Journal of Radiation Oncology, Biology, Physics (7)
  5. European Journal of Cancer (5)
  6. Transplantation and Cellular Therapy (5)

More Publications

Results (114)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Role of tumor microenvironment derived NRG1 in androgen resistance: Implications for a novel prostate cancer treatment strategy
    Meeting Abstract

    Shinder, B.; Mao, N.; Salsabeel, N.; Zhang, Z.; Sawyers, C. L.; Carver, B. S.
    Urologic Oncology: Seminars and Original Investigations (2024)

    Fulltext@MSK | Save
  • Carcinoma in situ and urinary cytology as an indicator of minimal residual disease in patients with non-muscle invasive bladder cancer treated with BCG
    Meeting Abstract

    Katims, A. B.; D'Souza, N.; De Jesus Escaño, M. R.; Gokturk, G.; Basar, M.; Solit, D. B.; Iyer, G.; Bochner, B. H.; Goh, A.; Donahue, T. A.; more...
    Urologic Oncology: Seminars and Original Investigations (2024)

    Fulltext@MSK | Save
  • Intraoperative radiation therapy for pediatric patients: A 25 year experience
    Meeting Abstract

    Conte, B.; Casey, D. L.; LaQuaglia, M. P.; Honeyman, J.; Narayan, N.; Wolden, S. L.
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • Salvage radiotherapy as a bridge for relapsed secondary CNS lymphoma
    Meeting Abstract

    Cederquist, G.; Tringale, K. R.; Hajj, C.; Hubbeling, H. G.; Sarkar, R. R.; Ma, J.; Dreyfuss, A.; Fregonese, B.; Lee, J.; Pike, L. R. G.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology
    Meeting Abstract

    Maclachlan, K.; Blaney, P.; Gagler, D.; Boyle, E.; Diamond, B.; Shah, U.; Korde, N.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Individualized risk in newly diagnosed multiple myeloma
    Meeting Abstract

    Maura, F.; Rajanna, A.; Ziccheddu, B.; Derkach, A.; Poos, A.; Maclachlan, K.; Boyle, E.; Hultcrantz, M.; Silva, A.; Jackson, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save